Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENIOR Trial: Senolytics for Osteoporosis
NCT06018467Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Sep 2023
- Primary completion
- Apr 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, quercetin, nicotinamide riboside in osteopenia, osteoporosis, sponsored by University Hospital Odense. Started Sep 2023; status: completed.
02
Drugs
dasatinibquercetinnicotinamide riboside
03
Conditions
osteopeniaosteoporosis
Beyond the preview
Go deeper on NCT06018467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018467.